Experimental drug SGR-2921 tested for tough blood cancers – but trial halted early
NCT ID NCT05961839
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an experimental oral drug called SGR-2921 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The main goals were to check safety and find the right dose. However, the study was terminated early, so no results are available yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SGR-2921 (an experimental oral drug)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat blood cancers.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so we don't know if the drug is safe or effective. Many early-stage drugs never make it to patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Oncology Associates of Oregon, P.C.
Eugene, Oregon, 97401, United States
-
Oregon Health & Science University - Knight Cancer Institute - Center of Hematologic Malignancies
Portland, Oregon, 97239, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
St. David's South Austin Medical Center
Austin, Texas, 78745, United States
-
The Ohio State University Wexner Medical Center - James Cancer Hospital
Columbus, Ohio, 43210, United States
-
The University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization
Philadelphia, Pennsylvania, 19107, United States
-
TriStar Bone Marrow Transplant, LLC
Nashville, Tennessee, 37203, United States